Published in J Infect Dis on March 01, 1992
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol (1993) 6.36
Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med (2003) 4.20
Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A (1994) 3.76
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol (1993) 2.57
Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. J Clin Microbiol (1993) 2.36
Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol (2002) 2.31
Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol (1998) 2.09
Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol (1999) 1.93
Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol (2003) 1.93
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A (2008) 1.82
An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol (1994) 1.68
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Hepatitis viruses: changing patterns of human disease. Proc Natl Acad Sci U S A (1994) 1.60
Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon (2013) 1.59
Retracted Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci U S A (2000) 1.51
Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol (1998) 1.48
Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines (2011) 1.37
Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol (2008) 1.33
Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology (2003) 1.32
Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol (2000) 1.20
Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol (2001) 1.17
Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J Virol (1998) 1.09
Patr-A and B, the orthologues of HLA-A and B, present hepatitis C virus epitopes to CD8+ cytotoxic T cells from two chronically infected chimpanzees. J Exp Med (1996) 1.08
Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. J Virol (1994) 1.07
DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol (1995) 1.03
Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol (2001) 1.02
Will there be a vaccine to prevent HCV infection? Semin Liver Dis (2014) 1.02
Prevalence and significance of hepatitis C virus (HCV) viremia in HCV antibody-positive subjects from various populations. J Clin Microbiol (1993) 0.99
Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol (1998) 0.97
Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection. World J Gastroenterol (2010) 0.95
Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol (2007) 0.95
Barriers of hepatitis C virus interspecies transmission. Virology (2013) 0.92
Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Eur J Clin Microbiol Infect Dis (2005) 0.90
Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol (1997) 0.87
Genotype dependence of hepatitis C virus antibodies detectable by the first-generation enzyme-linked immunosorbent assay with C100-3 protein. J Clin Invest (1993) 0.85
Serum Levels of Soluble IL-2R, CD4 and CD8 in Chronic Active HCV Positive Hepatitis. Mediators Inflamm (1994) 0.83
Chronic liver disease and active hepatitis C virus infection in patients with antibodies to this virus. J Clin Pathol (1994) 0.83
Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART). Hepatology (2007) 0.83
A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. Virol J (2007) 0.81
Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses (2009) 0.80
Advancement in the development of models for hepatitis C research. J Biomed Biotechnol (2012) 0.78
Peptide based enzyme immunoassays for detecting hepatitis C antibodies in sera of people at high risk. J Clin Pathol (1994) 0.75
Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies. Dig Dis Sci (2003) 0.75
Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet (1974) 2.77
Almost the entire 5' non-translated region of hepatitis C virus is required for cap-independent translation. FEBS Lett (1995) 2.72
Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses (1991) 2.52
Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 2.49
Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci U S A (1988) 2.47
Catenins and zonula occludens-1 form a complex during early stages in the assembly of tight junctions. J Cell Biol (1996) 2.37
Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet (1992) 2.25
Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology (1978) 2.09
In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood (1998) 1.98
Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen. Lancet (1973) 1.89
NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med (1988) 1.88
Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest (1996) 1.79
A genomic approach of the hepatitis C virus generates a protein interaction map. Gene (2000) 1.72
Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine (1986) 1.68
Familial clustering of hepatitis B infection. N Engl J Med (1973) 1.56
Hepatitis B antigen and antibody in blood donors: an epidemiologic study. J Infect Dis (1973) 1.46
The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion (1990) 1.45
Virulent HIV strains, chimpanzees, and trial vaccines. Science (1999) 1.40
Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. J Infect Dis (1987) 1.38
Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology (1998) 1.37
Molecular cloning and characterization of onchocystatin, a cysteine proteinase inhibitor of Onchocerca volvulus. J Biol Chem (1992) 1.33
Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood (1992) 1.22
The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant (2007) 1.19
Hypericin as an inactivator of infectious viruses in blood components. Transfusion (1995) 1.19
Identification of an immunodominant epitope within the capsid protein of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 1.18
Role of arthropods in transmission of hepatitis-B virus in the tropics. Lancet (1973) 1.17
Detection of virus-associated antigen in serum and liver of patients with non-A non-B hepatitis. Lancet (1979) 1.14
Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J Gen Virol (1999) 1.13
Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J Virol (1998) 1.09
Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol (2004) 1.09
DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology (2001) 1.08
Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine (1997) 1.08
Letter: Hepanosticon in screening for HBsAg. Lancet (1975) 1.07
Characterization of an Onchocerca volvulus cDNA clone encoding a genus specific antigen present in infective larvae and adult worms. Mol Biochem Parasitol (1991) 1.06
Full-genome sequence analyses of hepatitis B virus (HBV) strains recovered from chimpanzees infected in the wild: implications for an origin of HBV. Virology (2000) 1.06
Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans. J Infect Dis (1999) 1.06
Cloning of a cysteine protease required for the molting of Onchocerca volvulus third stage larvae. J Biol Chem (1996) 1.05
DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol (1995) 1.03
Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol (2001) 1.02
An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine (2007) 1.02
Transglutaminase-catalyzed reaction is important for molting of Onchocerca volvulus third-stage larvae. Antimicrob Agents Chemother (1995) 1.00
Experimental onchocerciasis in chimpanzees. Cell-mediated immune responses, and production and effects of IL-1 and IL-2 with Onchocerca volvulus infection. J Immunol (1991) 0.98
Characterization of an Onchocerca volvulus L3-specific larval antigen, Ov-ALT-1. Mol Biochem Parasitol (1998) 0.98
Isolation of a virus from chimpanzee liver cell cultures inoculated with sera containing the agent of non-A, non-B hepatitis. Lancet (1984) 0.96
Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol (1999) 0.95
Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet (1986) 0.95
Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating. AIDS Res Hum Retroviruses (1992) 0.95
Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. J Hepatol (2001) 0.94
Interference between non-A, non-B and hepatitis B virus infection in chimpanzees. J Med Virol (1983) 0.93
In vitro and in vivo replication capacity of the precore region defective hepatitis B virus variants. J Hepatol (1991) 0.92
High-temperature short-time heat inactivation of HIV and other viruses in human blood plasma. Vox Sang (1992) 0.92
Identification and characterization of an Onchocerca volvulus cDNA clone encoding a highly immunogenic calponin-like protein. Mol Biochem Parasitol (1994) 0.89
Onchocerca volvulus: biochemical and morphological characteristics of the surface of third- and fourth-stage larvae. Exp Parasitol (1990) 0.89
A correlated thin-section and freeze-fracture analysis of guinea pig adrenocortical cells. Am J Anat (1979) 0.89
Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol (1999) 0.89
Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepat (2002) 0.88
Strategies for evaluation of enveloped virus inactivation in red cell concentrates using hypericin. Photochem Photobiol (2000) 0.88
Ivermectin prophylaxis against experimental Onchocerca volvulus infection in chimpanzees. Am J Trop Med Hyg (1988) 0.87
Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology (2001) 0.87
Diagnostic tests for choreoacanthocytosis. Neurology (1991) 0.87
Immune response to epitopes of hepatitis C virus (HCV) structural proteins in HCV-infected humans and chimpanzees. J Infect Dis (1996) 0.86
Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant (2008) 0.85
Identification and characterization of an Onchocerca volvulus cDNA clone encoding a microfilarial surface-associated antigen. Mol Biochem Parasitol (1992) 0.85
Do filarid nematodes have a vascular system? Parasitol Today (1999) 0.85
Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion (2001) 0.84
beta-propiolactone/ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives. Rev Infect Dis (1983) 0.84
Biosynthesis of spectrin and its assembly into the cytoskeletal system of Friend erythroleukemia cells. J Cell Biol (1986) 0.84
In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides. Antimicrob Agents Chemother (1996) 0.83
Non-A, non-B hepatitis: is there more than a single blood-borne strain? J Infect Dis (1985) 0.83
Evaluation of hepatitis C virus protein epitopes for vaccine development. Trends Biotechnol (1996) 0.83
Onchocerca volvulus: in vitro killing of microfilaria by neutrophils and eosinophils from experimentally infected chimpanzees. Trop Med Parasitol (1991) 0.83
Epidemiology of hepatitis B infection in Liberian infants. Infect Immun (1981) 0.82
A novel developmentally regulated galectin of Onchocerca volvulus. Mol Biochem Parasitol (2000) 0.82
Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes. Hepatology (1998) 0.82
Soluble HLA-G in heart transplantation: their relationship to rejection episodes and immunosuppressive therapy. Hum Immunol (2006) 0.82
Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections. J Viral Hepat (2004) 0.82
Neutralizing antibody to the AIDS virus. Prevalence, clinical significance and virus strain specificity. Antibiot Chemother (1971) (1987) 0.82
Inactivation of hepatitis B and non-A, non-B viruses by combined use of Tween 80, beta-propiolactone, and ultraviolet irradiation. Thromb Haemost (1983) 0.81
Onchocerca volvulus: immunization of chimpanzees with X-irradiated third-stage (L3) larvae. Exp Parasitol (1992) 0.81
Effect of phosphatidylserine on the shape of McLeod red cell acanthocytes. Blood (1989) 0.81
A final report on safety and immunogenicity of a bivalent aqueous subunit HBV vaccine. J Med Virol (1985) 0.81
Patterns and prevalence of hepatitis C virus infection in posttransfusion non-A, non-B hepatitis. J Infect Dis (1993) 0.81
Hepatitis B virus proteins eliciting protective immunity. Microbiol Sci (1987) 0.81
Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol (2002) 0.80
[Dendritic cells and hepatitis C virus]. Pathol Biol (Paris) (2001) 0.80
Onchocera volvulus: characterization of a highly immunogenic Gln-rich protein. Mol Biochem Parasitol (1997) 0.80